An Early Phase 1 interventional study of FSH/LH in Sub-Fertility, sponsored by Hospital de Cruces. Completed. Open to female participants aged 35 Years to 40 Years. Per ClinicalTrials.gov, last updated 2022-08-04.
Sponsored by Hospital de Cruces · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing Follicle Stimulating Hormone in Infertility — 1 open to participants now, 1 under way, none of them phase 3. Follicle Stimulating Hormone · Infertility.
Among the 12 studies testing Follicle Stimulating Hormone in Infertility, this one is the 3rd largest by enrollment, is the only one that started in 2017, is one of 2 in phase 1, and was the 10th registered.
2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →1 of the 12 studies testing Follicle Stimulating Hormone in Infertility is open now, in 1 country. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 19–37 · Women only · Healthy volunteers
By country, each count listing its studies:
Follicle Stimulating Hormone: first FDA approval 1997 (GONAL-F). What it is approved for, and how studies give it, is on its page →
Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 35 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 447 is above the median of 133 across 1,415 interventional studies indexed under Infertility.
Median enrollment 239 across the 12 interventional studies. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 12 have an industry lead sponsor. The 10 most frequent:
Hospital de Cruces is the lead sponsor of 10 studies on the registry; none are open to participants now.
Hospital de Cruces has 1 study filed under Infertility — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing Follicle Stimulating Hormone in Infertility, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to compare different FSH/LH ratios in controlled ovarian stimulation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
dose: 300IU FSHrec and 150IU LHrec
Drug: FSH/LH
dose: 300IU FSHrec and 75IU LHrec
Drug: FSH/LH
Drug page: Follicle Stimulating HormoneStudies of Follicle Stimulating HormoneFollicle Stimulating Hormone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Pregnancy achievement
To report our results in terms of pregnancy per embryo transfer
Time frame: 3 months after drug administration
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2017 to primary completion in Dec 2017, 11 months.
Of 28 phase 1 interventional studies under Infertility, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 38. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follicle Stimulating Hormone
Hospital de Cruces